- Home
- MRCC vs NTHI Comparison
MRCC vs NTHI Comparison
Compare MRCC & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRCC
- NTHI
- Stock Information
- Founded
- MRCC 2011
- NTHI 2008
- Country
- MRCC United States
- NTHI United States
- Employees
- MRCC N/A
- NTHI N/A
- Industry
- MRCC Investment Managers
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- MRCC Finance
- NTHI Health Care
- Exchange
- MRCC Nasdaq
- NTHI Nasdaq
- Market Cap
- MRCC 176.4M
- NTHI 142.5M
- IPO Year
- MRCC 2012
- NTHI N/A
- Fundamental
- Price
- MRCC $6.32
- NTHI $3.75
- Analyst Decision
- MRCC Hold
- NTHI
- Analyst Count
- MRCC 1
- NTHI 0
- Target Price
- MRCC $8.00
- NTHI N/A
- AVG Volume (30 Days)
- MRCC 70.0K
- NTHI 24.1K
- Earning Date
- MRCC 08-06-2025
- NTHI 01-01-0001
- Dividend Yield
- MRCC 15.72%
- NTHI N/A
- EPS Growth
- MRCC 3301.50
- NTHI N/A
- EPS
- MRCC 0.32
- NTHI N/A
- Revenue
- MRCC $56,983,000.00
- NTHI $79,990.00
- Revenue This Year
- MRCC N/A
- NTHI N/A
- Revenue Next Year
- MRCC N/A
- NTHI N/A
- P/E Ratio
- MRCC $19.57
- NTHI N/A
- Revenue Growth
- MRCC N/A
- NTHI 13.52
- 52 Week Low
- MRCC $6.11
- NTHI $3.50
- 52 Week High
- MRCC $8.85
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- MRCC 35.57
- NTHI N/A
- Support Level
- MRCC $6.19
- NTHI N/A
- Resistance Level
- MRCC $6.42
- NTHI N/A
- Average True Range (ATR)
- MRCC 0.11
- NTHI 0.00
- MACD
- MRCC -0.02
- NTHI 0.00
- Stochastic Oscillator
- MRCC 8.77
- NTHI 0.00
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").